Volume | 258,311 |
|
|||||
News | - | ||||||
Day High | 21.64 | Low High |
|||||
Day Low | 20.4263 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cassava Sciences Inc | SAVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
20.4263 | 20.4263 | 21.64 | 20.74 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,076 | 258,311 | $ 21.05 | $ 5,437,326 | - | 12.3202 - 32.10 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:48:54 | 100 | $ 21.40 | USD |
Cassava Sciences (SAVA) Options Flow Summary
Cassava Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
12.1M | 43.23M | - | 0 | -97.22M | -2.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cassava Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.23 | 21.94 | 19.47 | 20.42 | 806,683 | 0.17 | 0.80% |
1 Month | 20.26 | 26.6757 | 19.435 | 22.12 | 1,005,340 | 1.14 | 5.63% |
3 Months | 24.27 | 26.6757 | 18.18 | 21.94 | 739,767 | -2.87 | -11.83% |
6 Months | 14.78 | 32.10 | 14.6115 | 23.24 | 1,018,902 | 6.62 | 44.79% |
1 Year | 22.70 | 32.10 | 12.3202 | 21.72 | 981,005 | -1.30 | -5.73% |
3 Years | 40.54 | 146.16 | 12.3202 | 49.63 | 2,377,071 | -19.14 | -47.21% |
5 Years | 1.10 | 146.16 | 1.00 | 34.20 | 2,782,863 | 20.30 | 1,845.45% |
Cassava Sciences Description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. |